PIQ (ASX) Ann: Study shows diabetes drug improves PromarkerD risk scores

Originally posted by Owl vs Fox: ↑

Hi Scotty,

Approved for use in Australia, but the reason Janssen withdrew it above, it all came down to the Australian Govt not wanting to subsidise the cost on the PBS without a 40% price cut.

This may change, initially at this time, SGLT2is were for glycaemic control only. The cardiorenal benefits were not in the equation.

Now with cardiorenal benefits demonstrated in a multitude of studies & drugs becoming less costly as time goes on and market competition. Cost vs benefit, a better argument for subsidising on the PBS with more indications/benefit.

There are other SGLT2is now available in Australia with comparable costs. As usual with newer drugs & indivations, we are miles behind the 8 ball in Australia.

It can be a battle to get higher cost drugs onto the PBS, they are approved for use, but out of reach of most of us without being subsidised.

Regardless, it doesn’t change PromarkerD utility as a prognostic test for Australians.

Clinical guidelines show evidence for using this class of drugs. A recent article from Royal Australian College of General Practitioners (RACGP):

https://www1.racgp.org.au/getattachment/3e2b9a1c-6ed5-45e2-b4e3-7f07d08efae6/Use-of-sodium-glucose-co-transporter-2-inhibitors.aspx

Having a potential clinical tool (CDx) to monitor the benefits for patients, when to potentially start them on the drug (Prognostic risk score), I think could also be a game changer.

GLTAH

Expand

Hi Owl, Sincere thanks for taking the time to provide a very thorough response to my query. Your insight and knowledge of PIQ is of great benefit to many to less experienced investors in this area.

Originally posted by Owl vs Fox: ↑

Hi Scotty,

Approved for use in Australia, but the reason Janssen withdrew it above, it all came down to the Australian Govt not wanting to subsidise the cost on the PBS without a 40% price cut.

This may change, initially at this time, SGLT2is were for glycaemic control only. The cardiorenal benefits were not in the equation.

Now with cardiorenal benefits demonstrated in a multitude of studies & drugs becoming less costly as time goes on and market competition. Cost vs benefit, a better argument for subsidising on the PBS with more indications/benefit.

There are other SGLT2is now available in Australia with comparable costs. As usual with newer drugs & indivations, we are miles behind the 8 ball in Australia.

It can be a battle to get higher cost drugs onto the PBS, they are approved for use, but out of reach of most of us without being subsidised.

Regardless, it doesn’t change PromarkerD utility as a prognostic test for Australians.

Clinical guidelines show evidence for using this class of drugs. A recent article from Royal Australian College of General Practitioners (RACGP):

https://www1.racgp.org.au/getattachment/3e2b9a1c-6ed5-45e2-b4e3-7f07d08efae6/Use-of-sodium-glucose-co-transporter-2-inhibitors.aspx

Having a potential clinical tool (CDx) to monitor the benefits for patients, when to potentially start them on the drug (Prognostic risk score), I think could also be a game changer.

GLTAH

Expand

Originally posted by Owl vs Fox: ↑

Hi Scotty,

Approved for use in Australia, but the reason Janssen withdrew it above, it all came down to the Australian Govt not wanting to subsidise the cost on the PBS without a 40% price cut.

This may change, initially at this time, SGLT2is were for glycaemic control only. The cardiorenal benefits were not in the equation.

Now with cardiorenal benefits demonstrated in a multitude of studies & drugs becoming less costly as time goes on and market competition. Cost vs benefit, a better argument for subsidising on the PBS with more indications/benefit.

There are other SGLT2is now available in Australia with comparable costs. As usual with newer drugs & indivations, we are miles behind the 8 ball in Australia.

It can be a battle to get higher cost drugs onto the PBS, they are approved for use, but out of reach of most of us without being subsidised.

Regardless, it doesn’t change PromarkerD utility as a prognostic test for Australians.

Clinical guidelines show evidence for using this class of drugs. A recent article from Royal Australian College of General Practitioners (RACGP):

https://www1.racgp.org.au/getattachment/3e2b9a1c-6ed5-45e2-b4e3-7f07d08efae6/Use-of-sodium-glucose-co-transporter-2-inhibitors.aspx

Having a potential clinical tool (CDx) to monitor the benefits for patients, when to potentially start them on the drug (Prognostic risk score), I think could also be a game changer.

GLTAH

Expand

No.	Vol.	Price($)
1	8000	87.0¢

No.

Vol.

Price($)

8000

87.0¢

Price($)	Vol.	No.
89.0¢	16900	1

Price($)

Vol.

No.

89.0¢

16900

No.	Vol.	Price($)
1	8000	0.870
1	7876	0.865
3	24118	0.850
2	2235	0.845
3	30550	0.840

No.

Vol.

Price($)

8000

0.870

7876

0.865

24118

0.850

2235

0.845

30550

0.840

Price($)	Vol.	No.
0.890	16900	1
0.900	14000	1
0.910	6202	1
0.920	3000	1
0.930	10000	1

Price($)

Vol.

No.

0.890

16900

0.900

14000

0.910

6202

0.920

3000

0.930

10000

(20min delay)
Last 88.0¢		Change -0.020(2.22%)		Mkt cap ! $115.1M

Open	High	Low	Value	Volume
91.0¢	91.0¢	86.5¢	$99.60K	112.5K

Ann: Study shows diabetes drug improves PromarkerD risk scores, page-36

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Ava Risk Group expands US presence with A$0.7M Substation Deal

Microcap Wrap: 5 explorers with news out today

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Recce's R327 found effective against E.coli during clinical trial

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Study shows diabetes drug improves PromarkerD risk scores, page-36

Top Stories

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Ava Risk Group expands US presence with A$0.7M Substation Deal

Microcap Wrap: 5 explorers with news out today

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Recce's R327 found effective against E.coli during clinical trial

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News